

Title of the submission to journal CCR

Full Name 1¹ Full Name 2¹ Full Name 3^{1,2} Full Name 4³

¹ Department, Institution, City/State (postcode), Country

² Department, Institution, City/State (postcode), Country

³ Department, Institution, City/State (postcode), Country

*Corresponding Author: Full Name, Affiliation, Institutional Email Address

Abstract: A single paragraph of about 300 words maximum. Authors should include an abstract which is a concise summary of a research paper that is fully self-contained and makes sense by itself. It should be informative for the readers and include the research purpose and the results achieved that are significant. Ideally, an abstract should be the last thing that the author writes after completing his manuscript. Authors should also include 5–8 keywords after the abstract and avoid using the words that have already been used in the title of the manuscript.

Keywords: keyword 1; keyword 2; keyword 3; keyword 4; keyword 5 (List five to eight pertinent keywords specific to the article yet reasonably common within the subject discipline.)

1 Introduction

The introduction of the paper should start with an explanation of why a particular research is being conducted and end with a statement/conclusion of the selected research approach. Authors must ensure that a non-technical reader is able to understand the introduction, including the technical goals and objectives, any technical issues faced and its application in the real world. It would be beneficial for the readers if the authors provided a clear, one sentence purpose statement of the research. It would be advisable to keep the length of the introduction about 1/2 page (1–2 paragraphs). References should be numbered in order of appearance and indicated by a numeral or numerals in square brackets—e.g., journal [1] or manuscript [2], or template [3,4,5,6]. See the end of the document for further details on references.

2 Materials and methods

In this section, authors are required to provide a detailed account of the procedure that was followed while conducting the research described in the report. This will help the readers to obtain a clear understanding of the research and also allow them to replicate the study in the future. Authors should ensure that every method used is described and include citations for the procedures that have been described previously. Avoid any kind of discussion in this section regarding the methods or results of any kind.

Research manuscripts reporting large datasets that are deposited in a publicly available database should specify where the data have been deposited and provide the relevant accession numbers. If the accession numbers have not yet been obtained at the time of submission, please state that they will be provided during review. They must be provided prior to publication.

Interventionary studies involving animals or humans, and other studies that require ethical approval, must list the authority that provided approval and the corresponding ethical approval code.

3 Results

This section may be divided by subheadings. It should provide a concise and precise description of the experimental results, their interpretation, as well as the experimental conclusions that can be drawn.

3.1 Subsection

3.1.1 Subsubsection

Bulleted lists look like this:

- First bullet;
- Second bullet;
- Third bullet.

Numbered lists can be added as follows:

- a) First item;
- b) Second item;
- c) Third item.

The text continues here.

3.2 Figures and tables

All figures and tables should be cited in the main text as Figure 1, Table 1, etc. Place figures as close as possible to the text they refer to and aligned center. Photos, graphs, charts or diagram should be labeled Figure (do not abbreviate), and assigned a number consecutively (Figure 1). The title should appear underneath the figure, aligned center, no additional blank line.




Figure 1 Figure lable.


Table 1 This is a table.

Title 1	Title 2	Title 3
Entry 1	data	data
Entry 2	data	data
Entry 3	data	data ¹


¹ Tables may have a footer.

In cases where the tables need to be extended over to the second page, the continuation of the table should be preceded by a caption, e.g., "Table 1 (Continued)". Footnotes in tables should be written in superscript lowercase letters and placed below the table.

The text continues here (Figure 2 and Table 2).



(a)



(b)

Figure 2 This is a figure. Schemes follow another format. If there are multiple panels, they should be listed as: (a) Description of what is contained in the first panel; (b) Description of what is contained in the second panel. Figures should be placed in the main text near to the first time they are cited.

Table 2 This is a table. Tables should be placed in the main text near to the first time they are cited.

Title 1	Title 2	Title 3	Title 4
	data	data	data
entry 1 *	data	data	data
	data	data	data
entry 2	data	data	data
	data	data	data
entry 3	data	data	data
	data	data	data
	data	data	data
entry 4	data	data	data
	data	data	data

* Tables may have a footer.

3.3 Formatting of mathematical components

Including symbols and equations in the text, the variable name and style must be consistent with those in the equations.

This is example 1 of an equation:

$$c = a + b \tag{1}$$

the text following an equation need not be a new paragraph. Please punctuate equations as regular text.

Theorem-type environments (including propositions, lemmas, corollaries etc.) can be formatted as follows:

Theorem 1. Example text of a theorem. Theorems, propositions, lemmas, etc. should be numbered sequentially (i.e., Proposition 2 follows Theorem 1). Examples or Remarks use the same formatting, but should be numbered separately, so a document may contain Theorem 1, Remark 1 and Example 1.

The text continues here. Proofs must be formatted as follows:

Proof of Theorem 1. Text of the proof. Note that the phrase “of Theorem 1” is optional if it is clear which theorem is being referred to. Always finish a proof with the following symbol.

The text continues here.

4 Discussion

Authors should discuss the results and how they can be interpreted from the perspective of previous studies and of the working hypotheses. The findings and their implications should be discussed in the broadest context possible. Future research directions may also be highlighted.

5 Conclusion

This section is not mandatory but can be added to the manuscript if the discussion is unusually long or complex.

Conflicts of interest

The authors declare that they have no conflict of interest.

Acknowledgments (optional)

Here, you can acknowledge any support given which is not covered by the author contribution or funding sections. This may include administrative and technical support, or donations in kind (e.g., materials used for experiments).

Funding Support (optional)

The detailed funding support information.

References

In-text Citations

References must be listed at the end of the manuscript and numbered in the order that they appear in the text. In the text, citations should be indicated by the reference number in superscript square brackets. An example: Negotiation research spans many disciplines (references according to [AMA Style](#)). References should include papers already published and those in “press”. Authors cannot cite any unavailable and unpublished work. Please use the style shown in the template of submission of manuscript. Note that “et al.” should only be used after three authors.

This section is compulsory and should be placed at the end of all manuscripts. Do not use footnotes or endnotes as a substitute for a reference list. The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should be excluded from this section. For references in reference list, all authors must be stated. Authors referenced are listed with their surname followed by their initials. All references should be sequenced according to the alphabetical order. References should follow [the AMA Style](#). If the DOI is available, please include it after the page range. The upper limitation of Reference total amount is 100, or author will be asked to revise and resubmit the manuscript.

- [1] Zuo M, Zheng G, Cao Y, et al. Hepatic arterial chemotherapy infusion combined with tyrosine kinase inhibitors and PD-1 inhibitors for advanced hepatocellular carcinoma with high-risk: A propensity score matching study. *International Journal of Surgery*. Published online July 12, 2024. <https://doi.org/10.1097/js9.0000000000001940>
- [2] Lin YD, Wu GS, Rao MY, et al. Effect of cytokines on advanced hepatocellular carcinoma prognosis receiving radiotherapy and tislelizumab plus anlotinib: a single-center phase II clinical trial. *Scientific Reports*. 2024, 14(1). <https://doi.org/10.1038/s41598-024-62523-z>
- [3] Tada T, Kumada T, Hiraoka A, et al. Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial. *Alimentary Pharmacology & Therapeutics*. 2024, 60(2): 233-245. <https://doi.org/10.1111/apt.18037>
- [4] Melero I, Yau T, Kang YK, et al. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. *Annals of Oncology*. 2024, 35(6): 537-548. <https://doi.org/10.1016/j.annonc.2024.03.005>
- [5] Chiang CL, Chiu KWH, Chan KSK, et al. Sequential transarterial chemoembolisation and stereotactic body radiotherapy followed by immunotherapy as conversion therapy for patients with locally advanced, unresectable hepatocellular carcinoma (START-FIT): a single-arm, phase 2 trial. *The Lancet Gastroenterology & Hepatology*. 2023, 8(2): 169-178. [https://doi.org/10.1016/s2468-1253\(22\)00339-9](https://doi.org/10.1016/s2468-1253(22)00339-9)
- [6] Liu D, Mu H, Liu C, et al. Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial. *Neoplasma*. 2024, 70(06): 811-818. https://doi.org/10.4149/neo_2023_230806n413
- [7] Zhang W, Tong S, Hu B, et al. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial. *Journal for ImmunoTherapy of Cancer*. 2023, 11(9): e007366. <https://doi.org/10.1136/jitc-2023-007366>
- [8] Li J, Kong M, Yu G, et al. Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma. *Frontiers in Immunology*. 2023, 14. <https://doi.org/10.3389/fimmu.2023.1188308>
- [9] Chen B, Huang B. Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab. *Liver International*. 2024, 44(7): 1735-1735. <https://doi.org/10.1111/liv.15944>